HealthEquity, Inc. (NASDAQ:HQY) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

HealthEquity, Inc. (NASDAQ:HQY) has earned a consensus recommendation of “Moderate Buy” from the thirteen research firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eleven have assigned a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $110.9286.

Several research firms have recently issued reports on HQY. Weiss Ratings upgraded shares of HealthEquity from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, June 5th. Royal Bank Of Canada increased their price objective on shares of HealthEquity from $100.00 to $108.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 3rd. KeyCorp reissued an “overweight” rating on shares of HealthEquity in a research note on Tuesday, May 26th. Wells Fargo & Company set a $111.00 target price on HealthEquity in a research report on Monday, June 1st. Finally, Barrington Research reaffirmed an “outperform” rating and set a $110.00 target price on shares of HealthEquity in a research note on Friday, May 22nd.

HealthEquity Stock Performance

NASDAQ HQY opened at $104.63 on Monday. The business’s 50 day moving average price is $93.37 and its 200-day moving average price is $85.79. HealthEquity has a fifty-two week low of $72.76 and a fifty-two week high of $106.42. The company has a market cap of $8.75 billion, a P/E ratio of 39.19, a P/E/G ratio of 1.76 and a beta of 0.21. The company has a debt-to-equity ratio of 0.46, a quick ratio of 3.44 and a current ratio of 3.44.

HealthEquity (NASDAQ:HQY) last issued its quarterly earnings results on Thursday, May 28th. The company reported $1.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.11 by $0.13. The company had revenue of $354.64 million during the quarter, compared to the consensus estimate of $352.02 million. HealthEquity had a return on equity of 14.75% and a net margin of 17.25%.HealthEquity’s quarterly revenue was up 7.2% on a year-over-year basis. HealthEquity has set its FY 2027 guidance at 2.880-2.950 EPS. Sell-side analysts predict that HealthEquity will post 3.92 earnings per share for the current year.

Insider Activity at HealthEquity

In other HealthEquity news, Director Gayle Furgurson Wellborn sold 2,439 shares of the company’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $90.00, for a total value of $219,510.00. Following the transaction, the director owned 19,733 shares of the company’s stock, valued at $1,775,970. This represents a 11.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Delano Ladd sold 7,500 shares of HealthEquity stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $90.00, for a total value of $675,000.00. Following the sale, the executive vice president owned 91,141 shares of the company’s stock, valued at approximately $8,202,690. This trade represents a 7.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 17,905 shares of company stock worth $1,651,280 in the last quarter. 1.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On HealthEquity

Large investors have recently added to or reduced their stakes in the stock. Sivia Capital Partners LLC purchased a new stake in shares of HealthEquity in the second quarter valued at approximately $306,000. Arrowstreet Capital Limited Partnership purchased a new position in HealthEquity during the 2nd quarter worth $4,747,000. Marshall Wace LLP purchased a new position in HealthEquity during the 2nd quarter worth $5,483,000. Amundi raised its position in HealthEquity by 9.3% during the 2nd quarter. Amundi now owns 30,203 shares of the company’s stock valued at $3,059,000 after purchasing an additional 2,574 shares in the last quarter. Finally, Jump Financial LLC purchased a new stake in shares of HealthEquity in the 2nd quarter worth $449,000. 99.55% of the stock is owned by hedge funds and other institutional investors.

HealthEquity Company Profile

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.